(1) the Furman inventors had an expectation that BCH- 189 would work for its
intended purpose, and
(2) Dr. Korba tested BCH- 189 for anti-HBV activity at the request of the FU7 an
inventors.
We note the following portions of Dr. Furman's testimony:
(A) Dr. Furman's testimony that the Furman inventors, upon leaming that BCH- 189
had anti-HrV activity (in 1989), discussed sending BCH- 189 to Dr. Korba for testing since "the
compound could exhibit activity against hepatitis B". (FF 24D ).
(B) Dr. Furman's testimony that once the Furman inventors learned that one of the
Liotta samples was BCH-1 89 (in August of 1990), they discussed sending the sample that was
BCH- 189 to Dr. Korba for anti-HBV testing (FF 24M); and
(C) Dr. Furman's testimony that Dr. Biron sent BCH-] 89 to Dr. Korba for anti-HBV
testing at the request of the Furman inventors. (FF 24N).
Dr. Furman's testimony indicates that, based on similarities in the active sites of the
reverse transcriptase enzyme of HIV and the polymerase enzyme of HBV, the Furman inventors
thought that BCH-189 "could" also have HBV activity. (FF 24C).
We are not sure that the Furman inventor's belief that BCH-189 "could" exhibit anti
HBV activity rises to the level of an gjaectation that BCH-189 would also have anti-HBV
activity. Nonetheless, even if we determine that the above portions of Dr. Furman's testimony
indicates such an expectation, Furman has not directed us to evidence corroborating these
portions of Dr. Furman's testimony. As noted above, inventor testimony used to establish prior
invention must be corroborated. We look to all the evidence pointed out to us by Furman,
31
Page: Previous 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Next
Last modified: November 3, 2007